Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Transplant BRaVE NHL
NL-OMON60717Phase 2Active, not recruiting
- Sponsor
- HOVON
- Start
- Mar 2018
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of brentuximab vedotin in diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMBCL) and non-Hodgkin lymphoma (NHL), sponsored by HOVON. Primary endpoints: Serious toxicity rate during cycles 1-2, Metabolic complete response rate after cycle 3 and 1 more. Started Mar 2018; status: active, not recruiting.
02
Drugs
brentuximab vedotin
03
Conditions
diffuse large B-cell lymphoma (DLBCL)primary mediastinal large B-cell lymphoma (PMBCL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NL-OMON60717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60717.